Table 1.
YQQRG elevated serum Alb levels and regulated lipid disorder.
| Time points (day) |
Sham | PAN | YQQRG | Fosinopril | |
|---|---|---|---|---|---|
| ALT (U/L) | 3 | 43.67 ± 3.21 | 39.33 ± 2.31 | 32.75 ± 2.75 | 39.5 ± 2.06 |
| 10 | 49.6 ± 7.02 | 43.67 ± 6.41 | 47.2 ± 9.58 | 43.0 ± 3.0 | |
| 15 | 42.0 ± 8.85 | 32.38 ± 7.17 | 32.33 ± 3.88 | 39.0 ± 5.14 | |
|
| |||||
| ASL (U/L) | 3 | 130.2 ± 8.1 | 119.98 ± 5.19 | 103.8 ± 7.21 | 119.67 ± 5.94 |
| 10 | 100.94 ± 9.15 | 73.54 ± 7.42 | 73.43 ± 18.89 | 71.74 ± 19.83 | |
| 15 | 155.28 ± 27.54 | 96.71 ± 22.07 | 122.12 ± 19.39 | 116.58 ± 16.90 | |
|
| |||||
| TP (mmol/L) | 3 | 50.6 ± 5.26 | 49.53 ± 5.0 | 50.88 ± 6.57 | 46.98 ± 5.43 |
| 10 | 49.98 ± 2.44 | 44.3 ± 3.50* | 46.96 ± 3.57 | 43.02 ± 2.47* | |
| 15 | 59.61 ± 9.68 | 49.44 ± 3.79* | 53.3 ± 7.32 | 52.33 ± 2.06* | |
|
| |||||
| Alb (g/L) | 3 | 34.03 ± 3.32 | 31.73 ± 2.68 | 32.88 ± 3.22 | 30.73 ± 2.31 |
| 10 | 32.4 ± 1.42 | 23.38 ± 2.39* | 24.87 ± 3.40* | 24.02 ± 3.05* | |
| 15 | 36.35 ± 4.35 | 27.06 ± 3.51* | 29.16 ± 3.20∗▲ | 30.06 ± 2.06∗▲ | |
|
| |||||
| BUN (mmol/L) | 3 | 10.18 ± 1.77 | 10.03 ± 1.59 | 9.6 ± 1.38 | 7.48 ± 1.03 |
| 10 | 5.82 ± 1.57 | 7.85 ± 0.66 | 6.73 ± 2.15 | 5.77 ± 1.40 | |
| 15 | 5.71 ± 1.40 | 6.33 ± 1.31 | 6.18 ± 0.73 | 7.14 ± 1.48 | |
|
| |||||
| Cre (μmol/L) | 3 | 33 ± 7.94 | 27.67 ± 5.13 | 27.0 ± 5.6 | 16.67 ± 0.47 |
| 10 | 25.6 ± 1.14 | 25.6 ± 3.91 | 26.33 ± 2.89 | 19.33 ± 1.53 | |
| 15 | 31.17 ± 3.82 | 27.14 ± 4.34 | 27.86 ± 5.08 | 25.28 ± 3.03 | |
|
| |||||
| TC (mmol/L) | 3 | 2.10 ± 0.07 | 1.94 ± 0.23 | 2.15 ± 0.09 | 2.01 ± 0.26 |
| 10 | 1.68 ± 0.13 | 4.95 ± 1.24* | 4.25 ± 1.29* | 4.27 ± 1.31* | |
| 15 | 1.87 ± 0.28 | 5.49 ± 1.47* | 4.11 ± 1.14∗▲ | 3.78 ± 0.98∗▲ | |
|
| |||||
| TG (mmol/L) | 3 | 0.57 ± 0.13 | 0.18 ± 0.03 | 0.33 ± 0.01 | 0.15 ± 0.02 |
| 10 | 0.74 ± 0.13 | 5.26 ± 1.76* | 1.63 ± 0.59▲ | 1.43 ± 0.41▲ | |
| 15 | 0.39 ± 0.14 | 2.24 ± 1.44* | 0.60 ± 0.36▲ | 0.51 ± 0.21▲ | |
|
| |||||
| HDL (mmol/L) | 3 | 1.54 ± 0.23 | 1.63 ± 0.21 | 2.16 ± 0.10 | 1.75 ± 0.19 |
| 10 | 1.41 ± 0.1 | 3.52 ± 0.63* | 3.37 ± 0.65* | 2.92 ± 0.62* | |
| 15 | 1.52 ± 0.15 | 4.06 ± 0.7* | 3.19 ± 0.74▲ | 3.0 ± 0.62▲ | |
|
| |||||
| LDL (mmol/L) | 3 | 0.84 ± 0.14 | 0.89 ± 0.13 | 1.1 ± 0.12 | 0.9 ± 0.10 |
| 10 | 0.63 ± 0.11 | 2.38 ± 0.67* | 2.51 ± 068* | 1.98 ± 0.48* | |
| 15 | 0.84 ± 0.12 | 2.18 ± 0.83* | 1.77 ± 0.63∗▲ | 1.6 ± 0.37∗▲ | |
There were significant decrease of TP, Alb, and elevation of TC, TG, HDL, and LDL levels of the PAN group compared with that of the sham group on days 10 and 15 (P < 0.05). YQQRG could significantly reduce TG at day 10. At day 15, YQQRG increased plasma levels of TP and Alb and reduced TC, TG, and LDL levels (*P < 0.05 compared with sham group; ▲ P < 0.05 compared with PAN). (ALT: alanine transarninase; AST: aspartate aminotransferase; Cre: creatinine; BUN: blood urea nitrogen; TP: total protein; Alb: albumin; TC: total cholesterol; TG: triglycerides; HDL: high density lipoprotein; and LDL: low density lipoprotein.)